$CAI News

Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection

Canaccord Genuity Maintains Hold on Caris Life Sciences, Raises Price Target to $30

Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026

TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $36

IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months

Caris Life Sciences Unveils the Next Evolution of Liquid Biopsy with Enhanced Caris Assure

Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look

Caris Life Sciences: Adjusting My Position After A Recent Steep Incline (Downgrade)

Caris Life Sciences Stock Jumped 10% Yesterday. Here’s Where Shares Could Go Further in 2026.

Caris Life Sciences: Diagnostics Growth With Room To Run

Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect

Could Caris Life Sciences (CAI) Be 7% Undervalued After Its Lung Cancer Research Update?

Caris Life Sciences (CAI) Will Present Seven Studies At A Global Lung Conference

Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer

Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer

Caris Life Sciences Announces Publication Of Study Validating An AI-Driven Approach To First-Line Treatment Selection In Pancreatic Cancer In The Journal 'npj Precision Oncology'

Caris Life Sciences, Inc. 2026 Q2 - Results - Earnings Call Presentation

What’s Next For Caris Life Sciences (CAI) After 21% Jump?

Caris Life Sciences, ECOG-ACRIN and NRG Oncology Study Demonstrates Multimodal AI Approach to Predict Late Distant Recurrence Risk in HR+ Early Breast Cancer